<p>Edgestream Partners L.P.在第二季度減持了 PTC Therapeutics, Inc.（納斯達克股票代碼：PTCT - 免費報告）的持股比例，根據該公司最近向美國證券交易委員會提交的 13F 申報文件，持有該生物製藥公司股票 22,080 股，較上一季度減持了 31,442 股。Edgestream Partners L.P.在最新報告期結束時持有的 PTC Therapeutics 股份價值 675,000 美元。</p>
<p>獲取 <strong>PTC Therapeutics</strong> 警報：</p>
<p>其他幾家機構投資者最近也對其持股進行了調整。Choreo LLC 在第二季度將其對 PTC Therapeutics 的持股比例提高了 4.1%。Choreo LLC 現在持有該生物製藥公司股票 11,426 股，價值 356,000 美元，較該期間增持了 452 股。亞利桑那州退休系統在第二季度將其對 PTC Therapeutics 的持股比例提高了 3.4%。亞利桑那州退休系統現在持有該生物製藥公司股票 19,301 股，價值 590,000 美元，較該期間增持了 636 股。Diversified Trust Co 在第二季度將其對 PTC Therapeutics 的持股比例提高了 5.6%。Diversified Trust Co 現在持有該生物製藥公司股票 15,317 股，價值 468,000 美元，較該期間增持了 818 股。ProShare Advisors LLC 在第一季度將其對 PTC Therapeutics 的持股比例提高了 9.3%。ProShare Advisors LLC 現在持有該生物製藥公司股票 18,313 股，價值 533,000 美元，較該期間增持了 1,564 股。最後，Allspring Global Investments Holdings LLC 在第一季度購入了 PTC Therapeutics 的新股份，價值約 46,000 美元。</p>
<h2>PTC Therapeutics 股價上漲 1.3%</h2>
<p>PTCT 股票週五開盤價為 36.64 美元。該公司的 50 天移動平均價格為 33.41 美元，200 天移動平均價格為 32.43 美元。該公司的市值為 28.1 億美元，市盈率為-4.77，貝塔係數為 0.64。PTC Therapeutics, Inc.的 12 個月最低價為 17.53 美元，最高價為 40.69 美元。</p>
<p>PTC Therapeutics（納斯達克股票代碼：PTCT - 獲取免費報告）於 8 月 8 日星期四發佈了其季度收益報告。該生物製藥公司報告的每股收益為（1.16）美元，低於分析師預期的（1.00）美元。該季度公司的營收為 1.867 億美元，低於分析師預期的 1.9212 億美元。根據股票分析師的平均預測，預計 PTC Therapeutics, Inc.今年將發佈-5.09 美元的每股收益。</p>
<h2>PTC Therapeutics 內部交易</h2>
<p>在其他 PTC Therapeutics 的消息中，首席財務官 Pierre Gravier 於 7 月 16 日星期二以每股 34.02 美元的平均價格出售了公司股票 2,269 股，總價值為 77,191.38 美元。交易完成後，首席財務官在公司持有 53,531 股股票，價值 1,821,124.62 美元。該交易已在向證券交易委員會提交的法律文件中披露，可通過此超鏈接訪問。目前公司 5.50% 的股份由內部持有。</p>
<h2>分析師設定新的價格目標</h2>
<p>許多分析師已對該公司發佈了報告。巴克萊將 PTC Therapeutics 的目標股價從 25.00 美元提高至 31.00 美元，並在 8 月 9 日星期五的研究報告中給予該公司 “等權重” 評級。羅伯特·W·貝爾德在 9 月 4 日星期三的研究報告中對 PTC Therapeutics 進行了覆蓋。他們給予該股票 “表現優異” 評級，並設定了 44.00 美元的目標股價。坎特菲茨傑拉德在 9 月 17 日星期二的研究報告中重申了 “超重” 評級，並對 PTC Therapeutics 的股票設定了 64.00 美元的目標股價。摩根大通在 6 月 20 日星期四的研究報告中重申了 “超重” 評級，並對 PTC Therapeutics 的股票設定了 53.00 美元的目標股價。最後，高盛集團將 PTC Therapeutics 的目標股價從 18.00 美元上調至 32.00 美元，並在 5 月 28 日星期二的研究報告中給予該股票 “賣出” 評級。三家分析機構給予該股票賣出評級，七家給予持有評級，六家給予買入評級，一家給予強烈買入評級。根據 MarketBeat.com 的數據，PTC Therapeutics 目前的平均評級為 “持有”，並且公司的共識目標股價為 37.64 美元。</p>
<p><strong>查看我們關於 PTCT 的最新報告</strong></p>
<h2>PTC Therapeutics 簡介（免費報告）</h2>
<p>PTC Therapeutics, Inc.是一家生物製藥公司，專注於在美國和國際市場為患有罕見疾病的患者發現、開發和銷售藥物。該公司提供 Translarna 和 Emflaza 用於治療杜興氏肌營養不良症；Upstaza 用於治療芳香族 L-氨基酸脱羧酶（AADC）缺乏症，一種中樞神經系統疾病；Tegsedi 和 Waylivra 用於治療罕見疾病；Evrysdi 用於治療成人和兒童的脊髓肌萎縮症（SMA）。</p>
<h2>閲讀更多</h2>
<ul>
<li>我們喜歡的五隻股票勝過 PTC Therapeutics</li>
<li>Russell 2000 指數，投資者如何利用它進行盈利交易</li>
<li>利用 Village Farms 股票，隨着大麻市場的發展</li>
<li>什麼是股息？購買最佳股息股票</li>
<li>MarketBeat 周評 - 9/16 - 9/20</li>
<li>ESG 股票，投資者應瞭解的內容</li>
<li>秋季獲利不容錯過的 3 只零售股</li>
</ul>
<p><strong>想看看其他對 PTCT 持有的對沖基金？</strong> 訪問 HoldingsChannel.com 獲取 PTC Therapeutics, Inc.（納斯達克股票代碼：PTCT - 免費報告）的最新 13F 申報和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFRDVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFRDVA"/></p>
<p><em>這則即時新聞警報是由敍事科技和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快速和最準確的報道。在發佈之前，這則報道經過了 MarketBeat 編輯團隊的審核。請將有關此報道的任何問題或評論發送至 contact@marketbeat.com。</em></p>
<p>→ 這個能夠拯救您退休金的 15 美元&#34;內幕秘密&#34;（來自市場幕後）(廣告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NDUx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NDUx"/></p>
<h2>現在是否值得投資 1000 美元在 PTC Therapeutics？</h2>
<p>在考慮投資 PTC Therapeutics 之前，您可能想要聽聽這個。</p>
<p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在應該購買的股票...而 PTC Therapeutics 並不在名單上。</p>
<p>儘管 PTC Therapeutics 目前在分析師中獲得&#34;持有&#34;評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

PTCT

<p>Edgestream Partners L.P.在第二季度將其對 PTC Therapeutics, Inc.的持股比例減少了 58.7%，現持有 22,080 股。其他投資者如 Choreo LLC 和亞利桑那州退休系統也調整了他們的持倉。PTC Therapeutics 股價上漲了 1.3%，達到 0.64 美元，市值為 18.1 億美元。該公司報告每股虧損 0.16 美元，低於預期。分析師對該股票的評級褒貶不一，平均目標價為 0.64 美元</p>

<p>Edgestream Partners L.P. lessened its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 58.7% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 22,080 shares of the biopharmaceutical company's stock after selling 31,442 shares during the quarter. Edgestream Partners L.P.'s holdings in PTC Therapeutics were worth $675,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Edgestream Partners L.P.在第二季度減持了 PTC Therapeutics, Inc.（納斯達克股票代碼：PTCT - 免費報告）的持股比例，根據該公司最近向美國證券交易委員會提交的 13F 申報文件，持有該生物製藥公司股票 22,080 股，較上一季度減持了 31,442 股。Edgestream Partners L.P.在最新報告期結束時持有的 PTC Therapeutics 股份價值 675,000 美元。</p>
</div><p>Get <strong>PTC Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>PTC Therapeutics</strong> 警報：</p>
</div><p>Several other institutional investors have also recently made changes to their positions in the company. Choreo LLC raised its position in shares of PTC Therapeutics by 4.1% during the 2nd quarter. Choreo LLC now owns 11,426 shares of the biopharmaceutical company's stock valued at $356,000 after buying an additional 452 shares during the period. Arizona State Retirement System raised its position in PTC Therapeutics by 3.4% in the second quarter. Arizona State Retirement System now owns 19,301 shares of the biopharmaceutical company's stock valued at $590,000 after purchasing an additional 636 shares during the period. Diversified Trust Co raised its position in PTC Therapeutics by 5.6% in the second quarter. Diversified Trust Co now owns 15,317 shares of the biopharmaceutical company's stock valued at $468,000 after purchasing an additional 818 shares during the period. ProShare Advisors LLC raised its position in PTC Therapeutics by 9.3% in the first quarter. ProShare Advisors LLC now owns 18,313 shares of the biopharmaceutical company's stock valued at $533,000 after purchasing an additional 1,564 shares during the period. Finally, Allspring Global Investments Holdings LLC purchased a new stake in PTC Therapeutics in the first quarter valued at approximately $46,000.</p>
<div class="lb-trans"><p>其他幾家機構投資者最近也對其持股進行了調整。Choreo LLC 在第二季度將其對 PTC Therapeutics 的持股比例提高了 4.1%。Choreo LLC 現在持有該生物製藥公司股票 11,426 股，價值 356,000 美元，較該期間增持了 452 股。亞利桑那州退休系統在第二季度將其對 PTC Therapeutics 的持股比例提高了 3.4%。亞利桑那州退休系統現在持有該生物製藥公司股票 19,301 股，價值 590,000 美元，較該期間增持了 636 股。Diversified Trust Co 在第二季度將其對 PTC Therapeutics 的持股比例提高了 5.6%。Diversified Trust Co 現在持有該生物製藥公司股票 15,317 股，價值 468,000 美元，較該期間增持了 818 股。ProShare Advisors LLC 在第一季度將其對 PTC Therapeutics 的持股比例提高了 9.3%。ProShare Advisors LLC 現在持有該生物製藥公司股票 18,313 股，價值 533,000 美元，較該期間增持了 1,564 股。最後，Allspring Global Investments Holdings LLC 在第一季度購入了 PTC Therapeutics 的新股份，價值約 46,000 美元。</p>
</div><h2>PTC Therapeutics Trading Up 1.3 %</h2>
<div class="lb-trans"><h2>PTC Therapeutics 股價上漲 1.3%</h2>
</div><p>Shares of PTCT stock opened at $36.64 on Friday. The firm has a fifty day moving average price of $33.41 and a 200 day moving average price of $32.43. The company has a market cap of $2.81 billion, a P/E ratio of -4.77 and a beta of 0.64. PTC Therapeutics, Inc. has a 12 month low of $17.53 and a 12 month high of $40.69.</p>
<div class="lb-trans"><p>PTCT 股票週五開盤價為 36.64 美元。該公司的 50 天移動平均價格為 33.41 美元，200 天移動平均價格為 32.43 美元。該公司的市值為 28.1 億美元，市盈率為-4.77，貝塔係數為 0.64。PTC Therapeutics, Inc.的 12 個月最低價為 17.53 美元，最高價為 40.69 美元。</p>
</div><p>PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing analysts' consensus estimates of ($1.00) by ($0.16). The company had revenue of $186.70 million for the quarter, compared to analysts' expectations of $192.12 million. On average, equities analysts forecast that PTC Therapeutics, Inc. will post -5.09 EPS for the current year.</p>
<div class="lb-trans"><p>PTC Therapeutics（納斯達克股票代碼：PTCT - 獲取免費報告）於 8 月 8 日星期四發佈了其季度收益報告。該生物製藥公司報告的每股收益為（1.16）美元，低於分析師預期的（1.00）美元。該季度公司的營收為 1.867 億美元，低於分析師預期的 1.9212 億美元。根據股票分析師的平均預測，預計 PTC Therapeutics, Inc.今年將發佈-5.09 美元的每股收益。</p>
</div><h2>Insider Buying and Selling at PTC Therapeutics</h2>
<div class="lb-trans"><h2>PTC Therapeutics 內部交易</h2>
</div><p>In other PTC Therapeutics news, CFO Pierre Gravier sold 2,269 shares of the company's stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $34.02, for a total value of $77,191.38. Following the completion of the transaction, the chief financial officer now owns 53,531 shares in the company, valued at $1,821,124.62. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. 5.50% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他 PTC Therapeutics 的消息中，首席財務官 Pierre Gravier 於 7 月 16 日星期二以每股 34.02 美元的平均價格出售了公司股票 2,269 股，總價值為 77,191.38 美元。交易完成後，首席財務官在公司持有 53,531 股股票，價值 1,821,124.62 美元。該交易已在向證券交易委員會提交的法律文件中披露，可通過此超鏈接訪問。目前公司 5.50% 的股份由內部持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的價格目標</h2>
</div><p>A number of analysts have issued reports on the company. Barclays boosted their target price on PTC Therapeutics from $25.00 to $31.00 and gave the company an &#34;equal weight&#34; rating in a research report on Friday, August 9th. Robert W. Baird assumed coverage on PTC Therapeutics in a research report on Wednesday, September 4th. They issued an &#34;outperform&#34; rating and a $44.00 target price on the stock. Cantor Fitzgerald reissued an &#34;overweight&#34; rating and issued a $64.00 target price on shares of PTC Therapeutics in a research report on Tuesday, September 17th. JPMorgan Chase &amp; Co. restated an &#34;overweight&#34; rating and issued a $53.00 price target on shares of PTC Therapeutics in a research note on Thursday, June 20th. Finally, The Goldman Sachs Group boosted their price target on shares of PTC Therapeutics from $18.00 to $32.00 and gave the stock a &#34;sell&#34; rating in a research note on Tuesday, May 28th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, PTC Therapeutics currently has an average rating of &#34;Hold&#34; and a consensus price target of $37.64.</p>
<div class="lb-trans"><p>許多分析師已對該公司發佈了報告。巴克萊將 PTC Therapeutics 的目標股價從 25.00 美元提高至 31.00 美元，並在 8 月 9 日星期五的研究報告中給予該公司 “等權重” 評級。羅伯特·W·貝爾德在 9 月 4 日星期三的研究報告中對 PTC Therapeutics 進行了覆蓋。他們給予該股票 “表現優異” 評級，並設定了 44.00 美元的目標股價。坎特菲茨傑拉德在 9 月 17 日星期二的研究報告中重申了 “超重” 評級，並對 PTC Therapeutics 的股票設定了 64.00 美元的目標股價。摩根大通在 6 月 20 日星期四的研究報告中重申了 “超重” 評級，並對 PTC Therapeutics 的股票設定了 53.00 美元的目標股價。最後，高盛集團將 PTC Therapeutics 的目標股價從 18.00 美元上調至 32.00 美元，並在 5 月 28 日星期二的研究報告中給予該股票 “賣出” 評級。三家分析機構給予該股票賣出評級，七家給予持有評級，六家給予買入評級，一家給予強烈買入評級。根據 MarketBeat.com 的數據，PTC Therapeutics 目前的平均評級為 “持有”，並且公司的共識目標股價為 37.64 美元。</p>
</div><p><strong>Check Out Our Latest Report on PTCT</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 PTCT 的最新報告</strong></p>
</div><h2>PTC Therapeutics Profile (Free Report)</h2>
<div class="lb-trans"><h2>PTC Therapeutics 簡介（免費報告）</h2>
</div><p>PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.</p>
<div class="lb-trans"><p>PTC Therapeutics, Inc.是一家生物製藥公司，專注於在美國和國際市場為患有罕見疾病的患者發現、開發和銷售藥物。該公司提供 Translarna 和 Emflaza 用於治療杜興氏肌營養不良症；Upstaza 用於治療芳香族 L-氨基酸脱羧酶（AADC）缺乏症，一種中樞神經系統疾病；Tegsedi 和 Waylivra 用於治療罕見疾病；Evrysdi 用於治療成人和兒童的脊髓肌萎縮症（SMA）。</p>
</div><h2>Read More</h2>
<ul>
<li>Five stocks we like better than PTC Therapeutics</li>
<li>Russell 2000 Index, How Investors Use it For Profitable Trading</li>
<li>Take Advantage of Village Farms Stock as Cannabis Market Evolves</li>
<li>What Are Dividends? Buy the Best Dividend Stocks</li>
<li>MarketBeat Week in Review – 9/16 - 9/20</li>
<li>ESG Stocks, What Investors Should Know</li>
<li>Don’t Miss These 3 Retail Stocks for Fall Gains</li>
</ul>
<div class="lb-trans"><h2>閲讀更多</h2>
<ul>
<li>我們喜歡的五隻股票勝過 PTC Therapeutics</li>
<li>Russell 2000 指數，投資者如何利用它進行盈利交易</li>
<li>利用 Village Farms 股票，隨着大麻市場的發展</li>
<li>什麼是股息？購買最佳股息股票</li>
<li>MarketBeat 周評 - 9/16 - 9/20</li>
<li>ESG 股票，投資者應瞭解的內容</li>
<li>秋季獲利不容錯過的 3 只零售股</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding PTCT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 PTCT 持有的對沖基金？</strong> 訪問 HoldingsChannel.com 獲取 PTC Therapeutics, Inc.（納斯達克股票代碼：PTCT - 免費報告）的最新 13F 申報和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFRDVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=PTCT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由敍事科技和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快速和最準確的報道。在發佈之前，這則報道經過了 MarketBeat 編輯團隊的審核。請將有關此報道的任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><p>→ The $15 &#34;Insider Secret&#34; That Could Save Your Retirement (From Behind the Markets)(Ad)</p>
<div class="lb-trans"><p>→ 這個能夠拯救您退休金的 15 美元&#34;內幕秘密&#34;（來自市場幕後）(廣告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05NDUx" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9451&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in PTC Therapeutics right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資 1000 美元在 PTC Therapeutics？</h2>
</div><p>Before you consider PTC Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 PTC Therapeutics 之前，您可能想要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PTC Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在應該購買的股票...而 PTC Therapeutics 並不在名單上。</p>
</div><p>While PTC Therapeutics currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 PTC Therapeutics 目前在分析師中獲得&#34;持有&#34;評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Edgestream Partners L.P. 減少了在 PTC Therapeutics, Inc. (NASDAQ:PTCT) 的持股